About BioBoyScout
BioBoyScout publishes deep, declarative investment research at the intersection of RNAi therapeutics, platform biology, and biotech mergers and acquisitions.
The publication is written by Robert Toczycki, JD/MBA — a Chicago-based independent investor focused on the next decade of RNA medicines, with particular depth on Arrowhead Pharmaceuticals (NASDAQ: ARWR), the broader RNAi competitive landscape, and the strategic acquisition logic of large pharma.
What you’ll find here
White papers. Long-form, institutional-grade research on platform valuation, pipeline economics, competitive positioning, and acquisition scenarios. Recent papers include The Setup (Analysis of ARO-MAPT’s Phase 1/2a Readout), The Endgame (ARWR acquisition valuation framework), The Year of Tau (ARO-MAPT scientific deep dive), The Needle Wins (auto-injector adoption and the RNAi tailwind), and Redemplo vs. Tryngolza (sHTG competitive analysis).
Notes and analysis. Shorter pieces tracking calendars, clinical readouts, competitive dynamics, M&A signals, and earnings reactions as they happen.
A structural rather than tactical view. BioBoyScout is not a trading newsletter. The work focuses on platform-level theses, pipeline economics, and multi-year strategic outcomes — written for readers who care about why something is happening, not just what is happening.
Who reads BioBoyScout
Institutional investors, sell-side analysts, biotech industry professionals, and serious individual investors who want primary-source research on the RNAi space and the companies competing within it.
Cadence
White papers roughly every two to four weeks. Shorter notes in between as catalysts and developments warrant.
About the author
Robert Toczycki is an independent analyst and registered US Patent Attorney with a JD, an Executive MBA completed at the top of his class, and a BS in Mathematics and Computer Science from the University of Illinois at Urbana-Champaign. He has been investing in biotech markets with a focus on RNA therapeutics, with particular conviction in the Arrowhead Pharmaceuticals platform. He writes under the BioBoyScout handle on X (@BioBoyScout), where the deeper analysis published here is condensed into ongoing market commentary.
Disclosures
The author maintains a long position in Arrowhead Pharmaceuticals (ARWR) and may hold positions in other companies discussed on this publication. BioBoyScout is independent research, not investment advice. Full disclosures are available here.
Contact
